Incyte
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 128
- Registration Number
- NCT06441318
- Locations
- ๐บ๐ธ
Celerion Clinical Research Unit, Tempe, Arizona, United States
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT06416800
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT06388564
- Locations
- ๐บ๐ธ
City of Hope Medical Center, Duarte, California, United States
๐บ๐ธUniversity of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic, Los Angeles, California, United States
๐บ๐ธMayo Clinic Hospital, Phoenix, Arizona, United States
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
- Conditions
- Interventions
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06380205
- Locations
- ๐บ๐ธ
Celerion Clinical Research Unit, Tempe, Arizona, United States
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 66
- Registration Number
- NCT06313593
- Locations
- ๐บ๐ธ
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
๐บ๐ธStanford University, Palo Alto, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06310304
- Locations
- ๐บ๐ธ
Celerion, Inc, Lincoln, Nebraska, United States
A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT06309394
- Locations
- ๐ฌ๐ง
Quotient Sciences Ltd, Nottingham, United Kingdom
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 958
- Registration Number
- NCT06259669
- Locations
- ๐บ๐ธ
Syneos Health (remote site), Morrisville, North Carolina, United States
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 225
- Registration Number
- NCT06238817
- Locations
- ๐ซ๐ท
Ghicl - Hรดpital Saint-Vincent de Paul, Lille Cedex, France
๐ซ๐ทChru de Lille Hopital Claude Huriez, Lille Cedex, France
๐ซ๐ทCentre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu, Nantes, France
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 960
- Registration Number
- NCT06212999
- Locations
- ๐บ๐ธ
Investigative Site US303, Phoenix, Arizona, United States
๐บ๐ธInvestigator Site US240, Scottsdale, Arizona, United States
๐บ๐ธInvestigative Site US307, Fort Smith, Arkansas, United States